<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823081</url>
  </required_header>
  <id_info>
    <org_study_id>91128</org_study_id>
    <nct_id>NCT01823081</nct_id>
  </id_info>
  <brief_title>Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible eyes are randomized to two groups. Group A will receive three intravitreal&#xD;
      injections of bevacizumab at 4 week intervals. In group B, three intravitreal injections of&#xD;
      combined bevacizumab and fasudil will be performed with the same frequency.&#xD;
&#xD;
      Best corrected visual acuity (BCVA) and central macular thickness (CMT) will be evaluated&#xD;
      prior to injections and then every 4 weeks for 6 months. Fluorescein angiography will be&#xD;
      performed at baseline and at weeks 12 and 24. The two groups will be compared in terms of&#xD;
      BCVA and CMT changes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Snellen E-chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>central macular thickness</measure>
    <time_frame>6 months</time_frame>
    <description>spectral domain optical coherence tomography (SD OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Status of macular perfusion</measure>
    <time_frame>6 months</time_frame>
    <description>Heidelberg fluorescein angiogram (HRA II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>clinical examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Intravitreal bevacizumab (Avastin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined intravitreal fasudil and bevacizumab (Avastin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of bevacizumab (Avastin)</intervention_name>
    <arm_group_label>Intravitreal bevacizumab (Avastin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of fasudil and bevacizumab (Avastin)</intervention_name>
    <description>intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)</description>
    <arm_group_label>Combined intravitreal fasudil and bevacizumab (Avastin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients with diabetic macular edema (DME) and:&#xD;
&#xD;
          -  Central macula thickness&gt; 250Î¼m&#xD;
&#xD;
          -  Visual acuity &lt; 20/40&#xD;
&#xD;
          -  No active proliferative diabetic retinopathy&#xD;
&#xD;
          -  No history of intravitreal anti-VEGF drug injection or macular laser photocoagulation&#xD;
             (MPC) within the past 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of vitrectomy&#xD;
&#xD;
          -  History of cataract surgery within the past 6 months&#xD;
&#xD;
          -  History of glaucoma or uveitis&#xD;
&#xD;
          -  Presence of any macular disorder other than DME&#xD;
&#xD;
          -  Presence of traction on the macula&#xD;
&#xD;
          -  Significant media opacity&#xD;
&#xD;
          -  Serum creatinine&gt;3mg/ml&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Clinical Professor, Ophthalmic Research Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fasudil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

